INCA-6

Research use only, not for human use.

INCA-6 is an inhibitor of Nuclear factor of activated T cells (NFAT) and calcineurin-NFAT signaling.

INCA-6 is an inhibitor of Nuclear factor of activated T cells (NFAT) and calcineurin-NFAT signaling.(In Vitro):In human retinal microvascular endothelial cells, INCA-6 (1.0, 2.5 μM) significantly decreases VEGF and serum-induced proliferation without affecting baseline proliferation. In 3-Hz cells, INCA-6 (5 μM) prevents transient outward K+ current downregulation. INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in rat primary microglia and BV-2 cells. INCA-6 (5 μM) protein expression and reduces SERCA2 transcript levels with and without thapsigargin.(In Vivo):INCA-6 (2.5, 5.0, and 25.0 μM; intravitreal) significantly reduces pathologic neovascularization in oxygen-induced retinopathy and decreases the severity of OIR in a dose dependent manner.

INCA-6 (5 μM; for 24-hour) prevents?transient outward K+?current (Ito)?downregulation in 3-Hz cells.Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia.?INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of ?thapsigargin (TG).INCA-6 (1.0 and 2.5 μM; 24 hours?) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation. Cell Proliferation Assay Cell Line:Human retinal microvascular endothelial cells Concentration:0.5, 1.0, or 2.5 μM Incubation Time:24 hours Result:Significantly inhibited VEGF-induced proliferation at 1.0 and 2.5 μM concentrations.

INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR). Animal Model:Rats bearing OIR model Dosage:2.5, 5.0, or 25.0 μM Administration:Intravitreal injection on days 14(0) and 14(3)Result:Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.

Triptycene-1,4-quinone

Others

Other Targets

prostaglandin F2α

——

——

3519-82-2

284.31

C20H12O2

>98% (HPLC)

In Vitro:?DMSO : 2.86 mg/mL (10.06 mM)

O=C1C=CC(=O)C2=C1C3C=4C=CC=CC4C2C=5C=CC=CC53

——

(-20℃)

With Ice Pack

≥ 2 years